Conclusions
CRS, CRC
DISEASE, APPENDICEAL CANCER
The findings of this randomized crossover trial, taking into consideration the lack of benefit from fluoropyrimidine-based chemotherapy seen in this trial and prior retrospective studies with similar conclusion, suggest that fluoropyrimidine-based chemotherapy should not be considered a standard-of-care treatment for patients with low-grade AA who are not candidates for CRS. Clinical trials investigating novel therapeutics should be considered for these patients. These prospective clinical data highlight the differences between AA and CRC and demonstrate the need for the development of appendiceal cancer–specific guidelines as well as more preclinical and clinical investigation for this disease.